Cargando…

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

MET amplification is a frequently observed genomic aberration in solid tumors. We conducted a phase I trial to evaluate dose-limiting toxicity (DLT) and recommended phase II dose (RP2D) for the combination therapy. The following dose levels were tested in this single-arm phase I study: docetaxel as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seung Tae, Lee, Sujin, Park, Minhwa, Park, Se Hoon, Park, Joon Oh, Lim, Ho Yeong, Park, Young Suk, Kang, Won Ki, Gangolli, Esha A., Shin, Hyeongchan, Kim, Kyoung-Mee, Hollingsworth, Simon J., Mortimer, Peter G.S., Lee, Jeeyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348337/ https://www.ncbi.nlm.nih.gov/pubmed/30695737 http://dx.doi.org/10.1016/j.tranon.2018.12.009

Ejemplares similares

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
por: Lim, Sung Won, et al.
Publicado: (2018)

To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients
por: Lee, Hansang, et al.
Publicado: (2016)

Savolitinib: A Promising Targeting Agent for Cancer
por: Lee, Tae Seung, et al.
Publicado: (2023)

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
por: Kim, Seung Tae, et al.
Publicado: (2016)

An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients
por: Lee, Ji Yun, et al.
Publicado: (2017)

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
por: Lee, Taehyang, et al.
Publicado: (2018)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
por: Jung, Ki Sun, et al.
Publicado: (2017)

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
por: Lim, Taekyu, et al.
Publicado: (2011)

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
por: Lee, Keun-Wook, et al.
Publicado: (2017)

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
por: Kim, Seung Tae, et al.
Publicado: (2020)

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
por: Hong, Jung Yong, et al.
Publicado: (2020)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
por: Kim, Seung Tae, et al.
Publicado: (2016)

MerTK is a novel therapeutic target in gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2015)

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021)

Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
por: Choi, Yunjung, et al.
Publicado: (2018)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
por: Kim, Hana, et al.
Publicado: (2021)

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis
por: Kim, Seung Tae, et al.
Publicado: (2017)

Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma
por: Lee, Su Jin, et al.
Publicado: (2014)

The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Moonjin, et al.
Publicado: (2016)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial
por: Park, Se Hoon, et al.
Publicado: (2005)

Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment
por: Lee, Min-Sang, et al.
Publicado: (2020)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

Comparison of Doxorubicin Plus Docetaxel Neoadjuvant Chemotherapy with Doxorubicin Plus Vinorelbine in Primary Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
por: Kim, Seung Tae, et al.
Publicado: (2015)

Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers
por: Lee, Su Jin, et al.
Publicado: (2020)

MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines
por: Kim, Jung Eun, et al.
Publicado: (2017)

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
por: Kim, Ju Sun, et al.
Publicado: (2017)

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
por: Lim, Sung Hee, et al.
Publicado: (2016)

A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer
por: Jo, Hyunji, et al.
Publicado: (2023)

Development of mesenchymal subtype gene signature for clinical application in gastric cancer
por: Lee, Jeeyun, et al.
Publicado: (2017)

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
por: Moon, Yong Wha, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v08pldi1gea2m8npmn0sag4t95